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A B S T R A C T
Alveolar echinococcosis (AE) is a severe zoonotic disease caused by the metacestode stage of
Echinococcus multilocularis. The infection can have fatal consequences in humans if treatment is not
provided, so early diagnosis is fundamental for initiating treatment and reducing morbidity and
mortality. In addition, detection of the parasite in the definitive host plays a central role in
epidemiological studies and surveillance programmes for control of AE. This review presents an
overview of the present situation regarding the immunodiagnosis of E. multilocularis infection. Special
attention is given to the description of the native, partially purified and recombinant antigens available
currently for immunodiagnostic purposes. Recent advances in the primary serodiagnosis and follow-up
of AE patients are highlighted, including the detection of specific cytokine profiles. Progress in the
immunodiagnosis of intestinal E. multilocularis infection in definitive hosts, particularly the detection of
excretory–secretory and integument products of the worm in faeces (copro-antigens) by ELISA, is also
discussed.
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I N T R O D U C T I O N
Alveolar echinococcosis (AE) is a severe zoonotic
disease caused by the larval stage (metacestode)
of the helminth Echinococcus multilocularis. The
life-cycle of the parasite is indirect and predom-
inantly sylvatic. Eggs produced by the adult
tapeworm are released with the faeces of the
definitive host (carnivores such as wild foxes,
other canids and, sporadically, felidae). When
these eggs are ingested by a suitable intermediate
host (typically rodents of the families Arvicolidae
and Cricetidae), the developing larva (onco-
sphere) is activated and differentiates into the
metacestode in the target organ. Humans can
serve as an aberrant intermediate host, acquiring
the infection by accidental ingestion of eggs.
The geographical distribution of AE is restrict-
ed to the northern hemisphere, where endemic
areas have been reported in parts of central
Europe (France, Switzerland, Germany and Aus-
tria), Russia, China, Japan, north America and
other countries [1]. In Europe, fox population
densities have increased in the last two decades
following successful vaccination campaigns
against rabies. This fact may have had important
consequences for the spread of E. multilocularis to
new endemic foci, including Denmark, The Neth-
erlands, Belgium, Luxemburg, Poland, the Czech
Republic, the Slovak Republic, Lithuania, Italy,
Romania and Hungary [2].
In humans, AE is a potentially fatal, chronically
progressive infestation produced by the multi-
vesiculated metacestode of E. multilocularis.
A characteristic feature of this stage is its exo-
genous tumour-like multi-vesicular, infiltrating
structure, consisting of numerous small vesicles
embedded in stroma of connective tissue [3]. In
most cases, the liver is the primary organ affected,
although secondary lesions (mainly in the lungs
and ⁄ or the brain) may result as a consequence of
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metastases in advanced cases of AE [3]. The slow
growth of the parasite means that no clinical
symptoms become evident until 10 or more years
after the initial infection, when the disease is
already well-advanced. Because of this, early
detection is important for initiating treatment and
reducing the morbidity and mortality [4]. Diagno-
sis of AE is based currently on identification of the
parasite’s structures by imaging techniques,
including ultrasound, computerised tomography
and magnetic resonance imaging [5–7]. However,
imaging techniques are relatively complex, do not
always offer a good prospect for early diagnosis,
and produce data that are sometimes difficult to
interpret, being often confused with those from
abscesses and neoplasms. In addition, imaging
technology is not always available in developing
countries with inadequately equipped medical
facilities. For these reasons, serological methods
using ELISA and western blot technology are
important not only for confirmation of AE cases,
but also for epidemiological studies in endemic
areas such as Germany [8,9], France [10] and China
[11–13]. Serological techniques are also very useful
for the follow-up of patients after surgical or
pharmacological treatment [14,15], and for the
specific differential diagnosis between AE and
cystic echinococcosis (CE) in those regions where
the diseases are co-endemic [16,17].
Although infection with E. multilocularis is typ-
ically asymptomatic in definitive hosts, detection
of the parasite in definitive host populations plays
a central role in epidemiological studies and AE
surveillance programmes [7]. Standard methods
for the diagnosis of E. multilocularis infection in a
definitive host involve post-mortem examination
using intestinal scrapings or sedimentation and
counting techniques [18]. While highly specific
and sensitive, these procedures are laborious,
require special safety precautions, and can be
used only with dead animals, which are charac-
teristics that limit their suitability for mass
screening. Conventional faecal egg detection can
be used for live animals, but eggs of Echinococcus
and Taenia spp. are morphologically identical and
cannot be differentiated by conventional micro-
scopy, and their production may be erratic. In
addition, detection of serum antibodies has
proved inadequate for estimating the prevalence
of the parasite in definitive hosts [5,18,19]. In an
attempt to improve the diagnosis of E. multilocularis
infection in a definitive host, ELISAs have been
successfully developed and evaluated for the
detection of parasite-specific copro-antigens
[20–22]. This simple, safe and relatively sensitive
technique allows detection of the parasite in both
necropsied and living definitive hosts, as well as
in faecal samples collected in the field. These
features make copro-antigen ELISA the method of
choice for routine mass screening and epidemio-
logical surveys [23], although confirmation of
copro-antigen ELISA-positive results by detection
of E. multilocularis DNA in faeces using PCR is
highly recommended for animal populations with
a low prevalence of the parasite [24].
A N T I G E N S F O R T H E
I M M U N O D I A G N O S I S O F A E
The search for highly sensitive and specific
antigens probably represents the greatest chal-
lenge in the immunodiagnosis of E. multilocularis
infection. Thus, in the last two decades, a wide
range of antigens from different developmental
stages of the parasite have been assayed for their
potential as candidate molecules for the sero-
diagnosis of AE in humans and other inter-
mediate hosts. In particular, the use of partially
purified and recombinant antigens has improved
the sensitivities and specificities of the diagnostic
tests considerably.
Metacestode antigens
The native Em2 antigen (also termed Em2a) was
purified originally from E. multilocularis metaces-
tode tissue extracts by affinity chromatography
[25]. This component had an apparent mass of
54 kDa, and analysis by western blot, immuno-
precipitation and ELISA demonstrated that it was
an E. multilocularis-specific antigen. Further
in-vivo and in-vitro studies revealed that Em2 is
a structural component found only in the meta-
cestode laminated layer, and not in freshly
hatched oncospheres, protoscolices or adult sta-
ges [26]. The laminated layer (glycocalix) is a
heavily glycosylated multi-vesicular structure
that is thought to play an important role as a
mediator of host–parasite interactions, protecting
the parasite from physiological and immuno-
logical host reactions [27,28]. The Em2 antigen
has been shown previously to be resistant to
proteinase K digestion and chloroform extraction,
providing evidence that this molecule could be
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largely carbohydrate in nature. This hypothesis
was confirmed by lectin-binding analysis,
which demonstrated that Em2 is composed of
b-D-galactose, N-acetyl-a-D-galactosamine, b-D-
galactose(1-3)-N-acetyl-D-galactosamine, (N-acet-
yl-D-glucosamine)2 and N-acetylsialic acid [29].
The glycosylated antigen Em2(G11) has been
found to be the major antigenic component of
Em2 [26]. Further studies by mass spectrometry
have revealed that the carbohydrate moieties of
Em2(G11) are solely galactose, N-acetylgalactosa-
mine and N-acetylglucosamine. In addition, ami-
no-acid analysis showed a large proportion of
threonine and proline residues, suggesting that a
mucin-type polypeptide core may be part of the
antigen structure [30]. With regard to its
immunogenic characteristics, Em2(G11) induces
non-specific in-vitro T-lymphocyte proliferation
in B-cell-deficient lMT mice, and low-avidity IgG
isotypes in vivo in C57BL ⁄ 6 mice [31]. These
findings seem to indicate that Em2(G11) is a
T-cell-independent antigen that could contribute
to the lack of protection against proliferation of
the parasite metacestode.
Em492 is an E. multilocularis metacestode com-
ponent identified recently by Walker et al. [32].
Lectin-binding analyses have shown that the
Em492 antigen appears to be a heterogeneous
fraction composed predominantly of O-linked
carbohydrate chains, N-linked sugars and, poss-
ibly, high-mannose-type core structures. Interest-
ingly, Em492 shares with Em2(G11) the
galactose-a(1,4)-galactose epitope, suggesting
that both antigens may be related immunologi-
cally. This hypothesis is supported by the fact
that Em492, as well as Em2(G11), is localised on
the laminated layer of the metacestode, and
seems also to be involved in the immunosup-
pressive events that occur at the host–parasite
interface. It has been proposed [32] that Em492
antigen may represent a breakdown product or a
sub-fraction of Em2(G11). The Echinococcus gra-
nulosus homologous component of Em492,
termed E4+, had been identified previously in
protoscolices, being involved in the modulation
of the cellular immune response in experimental
mice infections by stimulating interleukin (IL)-10
secretion and subsequent induction of the type 2
cytokine response [33]. Other E. granulosus anti-
gens with well-characterised glycosylate moieties
include the hydatid cyst fluid antigen 5 [34], the
blood group P1 epitope [35] and the carcinoma-
associated Tn antigen [36]. However, to our
knowledge, none of these components has been
described in E. multilocularis.
The enhanced diagnostic performance of Em2
(Table 1) has allowed its use for the immuno-
diagnosis of individual patients, for large-scale
seroepidemiological surveys [11,12,37–39], for the
follow-up of patients after surgery and ⁄ or therapy,
and for the detection ofE. multilocularis infection in
intermediate and aberrant hosts (see below). Inter-
estingly, Em2has been shown to share epitopes of a
peptidic nature with E. multilocularis alkaline
phosphatase (AP) [40]. Similarities between both
components, e.g., their co-localisation on the
metacestode laminated layer and their involve-
ment in important events at the host–parasite
interface, led to the suggestion that Em2 and the
parasite AP may be related functionally.
Table 1. Main characteristics of tests for serodiagnosis of human alveolar echinococcosis based on native and recombinant
antigens of the Echinococcus multilocularis metacestode
Antigen
No. of subjects tested
Test S (%) Sp (%) Cross-reactions ReferenceAE CE OD HS
Em2 88 108 112 355 IgG ELISA 92 98 CE [42]
Em2 140 124 276 500 IgG ELISA 89 94–100 CE [47]
Em2plus 140 124 276 500 IgG ELISA 97 74–99 CE, Schis., Fasc. [47]
Em2plus ELISA 103 103 35 – IgG ELISA 81 73 CE, Cys., Par. [60]
CH-10 140 124 276 500 IgG ELISA 96 39–97 CE, Cys., Fasc. [47]
N3C 140 124 276 500 IgG ELISA 96 18–94 CE, Cys., Fasc. [47]
pAP 37 44 51 37 IgG ELISA 100 100 None [92]
Em70 39 109 66 32 IB 100 99 CE [62]
Em90 39 109 66 32 IB 100 99 CE [62]
rII ⁄ 3 41 31 36 17 IgG IB 98 96 CE, Cys. [41]
rII ⁄ 3-10 88 108 107 355 IgG ELISA 90 99 CE, Cys. [42]
rII ⁄ 3-10 140 124 276 500 IgG ELISA 86 93–98 CE, Cys. [47]
rEM10 18 55 10 5 IgG IB 100 100 None [43]
rEM10 74 64 31 39 Total Ig ELISA 93 97 CE, Cys. [44]
AE, alveolar echinococcosis; CE, cystic echinococcosis; OD, other diseases; HS, healthy subjects; S, sensitivity; Sp, specificity; r, recombinant antigen; IB, immunoblotting;
Cys., cysticercosis; Fasc., fascioliasis; Par., paragonimiasis; Schis., schistosomiasis.
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The II ⁄ 3 gene was the first E. multilocularis
antigen gene to be cloned for immunodiagnostic
purposes [41]. The II ⁄ 3 recombinant antigen,
obtained from a cDNA library of the E. multilo-
cularismetacestode, was expressed as two distinct
polypeptides of 31 and 33 kDa, respectively,
probably generated by partial proteolysis of the
original fusion protein. Although II ⁄ 3 showed a
good serodiagnostic performance, problems asso-
ciated with its purification and its low expression
level hampered its use in routine diagnosis. In
order to overcome these inconveniences, a trun-
cated sequence of the original II ⁄ 3 gene, referred
to as II ⁄ 3-10, was sub-cloned and expressed as a
recombinant protein [42]. II ⁄ 3-10 retained the
most suitable diagnostic epitopes, and achieved
a similar diagnostic preformance to that of Em2.
The full-length cDNA sequence of II ⁄ 3 has been
cloned from a cDNA library of E. multilocularis
protoscolex [43]. The recombinant protein, named
EM10, had an apparent mass of 65 kDa and was
shown to be expressed on the germinal layer of
undifferentiated larval tissue and the tegument of
mature protoescolex. An evaluation of the diag-
nostic features of EM10 revealed that this com-
ponent distinguished between AE and CE with
very high specificity [44].
Interestingly, EM10 shows various degrees of
homology with other proteins characterised
previously. Thus, EM10 exhibits 42.6% identity
to human cytovillin, a protein found in the
plasma membrane of several carcinoma cells,
suggesting that this component may be associ-
ated with the invasive growth of the parasite
metacestode [43]. In addition, EM10 shows
46.9% overall identity to human ezrin, a protein
of the ERM family. Members of this family are
cytoskeletal effector proteins that link actin to
membrane-bound proteins at the cell surface.
However, the precise role of EM10 in the
parasite physiology remains to be elucidated
[45]. The EM10 homologous protein in E. gra-
nulosus, named EG10, has been shown to be
expressed differentially in different parasite
isolates, indicating that modifications during
the maturation of the antigen, or post-transcrip-
tional regulatory processing, may occur [46].
Em2 and II ⁄ 3-10 have been used simultaneously
in an ELISA (known as Em2plus ELISA), show-
ing excellent specificity and only a minor loss in
diagnostic sensitivity [47]. This test is currently
available commercially for the serodiagnosis of
AE in humans (Em2plus ELISA; Bordier Affinity
Products, Crissier, Switzerland).
The lipoprotein antigen B (AgB) and antigen 5
(Ag5), which are major components of the E. gra-
nulosus hydatid cyst fluid, are some of the most
interesting antigens available currently for the
serodiagnosis of CE [5,48]. AgB is encoded by a
multi-gene family that is expressed variably, with
at least four major gene clusters, named EgAgB1–
EgAgB4 [49]. Molecular studies have revealed that
AgB is also expressed in E. multilocularis, where
five cDNAs encoding 8-kDa subunit monomers of
EmAgB (termed EmAgB8 ⁄ 1–EmAgB8 ⁄ 5) have
been described [50,51]. EmAgB8 ⁄ 1–EmAgB8 ⁄ 4
showed >90% homology at both the nucleotide
and amino-acid levels with EgAgB1–EgAgB4,
while the remaining clone, EmAgB8 ⁄ 5, represents
a novel gene encoding another 8-kDa sub-unit
monomer of EmAgB. The fact that these isoforms
have been isolated from vesicles, protoscoleces
and immature adult worms suggests that differ-
ential expression occurs throughout the develop-
mental stages of E. multilocularis [51,52].
An assessment of the recombinant EmAgB8 ⁄
1–EmAgB8 ⁄ 4 proteins for serodiagnostic purpos-
es has not yet been undertaken, although the high
degree of identity at the amino-acid level with
their homologous E. granulosus components pre-
dicts an elevated level of cross-reactivity with sera
from CE patients. With regard to Ag5, a partial
cDNA sequence encoding a protein named Em6
has been isolated from a cDNA library of E. mul-
tilocularis protoscolex [53]. This component dis-
played 99% identity at the amino-acid level with
Eg6, a peptidic fragment of the E. granulosus Ag5
protein. In addition, the native Em6 was identi-
fied as a 40-kDa polypeptide in extracts from
fertile metacestodes and adult worms, but not
from non-fertile metacestodes, suggesting differ-
ential regulation of expression of Em6 during the
parasite developmental cycle. An evaluation of
the diagnostic potential of Em6 has not yet been
performed. The diagnostic performance of native
and recombinant antigens obtained from the
E. multilocularis metacestode in the immunodiag-
nosis of human AE is summarised in Table 1.
Protoscolex and adult somatic antigens
The EM2 clone was isolated from a cDNA library
of E. multilocularis protoscolex [54]. The native
EM2 protein was identified as a 70-kDa
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component in protoscolex and a crude
E. multilocularis antigen extract. Preliminary
immunodiagnostic evaluation of EM2 by western
blot initially revealed cross-reactions only with
sera from patients infected with E. granulosus,
although these results were not confirmed using a
larger panel of human sera. Subsequent investi-
gations led to the identification of the EM13 clone
from a cDNA library of E. multilocularis meta-
cestode [55]. The native EM13 protein was
expressed specifically in protoscolex as a 47-kDa
component, but could not be detected in
E. granulosus extracts. Interestingly, northern blot
analysis revealed that EM13 is transcribed in both
echinococcal species, suggesting that modifi-
cations during the maturation of the protein or
post-transcriptional regulatory processing may
occur. A similar phenomenon has been described
for the EM10 ⁄EG10 antigens [46] and the
Em18 ⁄Eg18 proteins [56]. Recombinant EM13
antigen also showed suitable features for the
serodiagnosis of human AE.
In an attempt to improve the immunodiagnosis
of AE by western blot, Ito et al. [57] identified two
specific antigenic components of E. multilocularis
protoscolex, designated Em18 and Em16, which
were detectable exclusively with sera from active
AE patients. The 18-kDa component was recog-
nised by sera from all active AE patients, whereas
the 16-kDa antigen was characteristically identi-
fied in patients with advanced lesions. Although
native Em18 and Em16 molecules were thought
initially to be species-specific, further investiga-
tions demonstrated that both antigens were also
recognised by sera from CE patients [58,59]. An
improved ELISA system that uses a partially
Em18 ⁄ 16-enriched fraction prepared by isoelectric
focusing has also been assessed for serodiagnostic
purposes [60]. The diagnostic performance of this
test was better than that of the Em2plus ELISA,
although a false-positive rate of 23.2% was
observed for CE patient sera.
Subsequent investigations, based on proteinase
inhibition analysis, revealed that Em18 was the
product of proteinase-mediated proteolysis of
EM10 by cysteine proteinase [61]. In this study,
recombinant Em18 protein was prepared by sub-
cloning the sequence fragment derived from 349K
to 508K of the EM10 antigen, followed by evalu-
ation of its diagnostic value by both ELISA and
western blot. The results obtained showed a
considerable improvement on the diagnostic sen-
sitivity and specificity of native Em18. In order to
identify the immunodominant regions of the
recombinant Em18 antigen, two clones, termed
Em18-1 and Em18-2, were isolated from a cDNA
library of E. multilocularis protoscolex [56]. Both
recombinant proteins shared the same sequence,
but a 27-bp (nine amino-acid) deletion occurred in
Em18-2, which was found not to be required for
recognition by immune sera. Immunological
assays with a large panel of monoclonal antibod-
ies revealed that immunoreactive epitopes were
located in the N-terminal third of the sequence
(amino-acids 1–117), whereas the non-specific
cross-reactivity was associated with epitopes pre-
sent in the C-terminal third of the sequence
(amino-acids 117–160). Removal of the latter led
to a considerable improvement in the diagnostic
sensitivity in both ELISA and western blot tests
(Table 2). It was also found that the ELISA assay
had a performance superior to western blot,
suggesting that there may be conformational
changes in the epitopes as a consequence of the
different sample preparation procedures.
Two new polypeptides of the E. multilocularis
metacestode, referred as to Em70 and Em90, have
also been proposed as potential antigens for the
Table 2. Main characteristics of tests for serodiagnosis of human alveolar echinococcosis based on native and recombinant
antigens of Echinococcus multilocularis protoscolex and ⁄or adults
Antigen
No. of subjects tested
Test S (%) Sp (%) Cross-reactions ReferenceAE CE OD HS
rEM4 49 11 11 – IgG ELISA 37 100 None [64]
EM13 28 55 15 2 IgG ELISA 82 100 None [55]
Em18 ⁄ 16 103 103 35 – IgG IB 93 73 CE [60]
Em18 66 173 71 29 IgG IB 97 97 CE [75]
rEm18 31 33 10 15 IgG ELISA ⁄ IB 87 ⁄ 90 98 ⁄ 98 CE [61]
rEm18-1 41 51 49 40 IgG ELISA ⁄ IB 95 ⁄ 95 94 ⁄ 81 CE, Cys., Schis., Hc., HS [56]
rEm18-2 41 51 49 40 IgG ELISA ⁄ IB 95 ⁄ 95 96 ⁄ 83 CE, Cys., Schis., Hc., HS [56]
AE, alveolar echinococcosis; CE, cystic echinococcosis; OD, other diseases; HS, healthy subjects; S, sensitivity; Sp, specificity; r, recombinant antigen; IB, immunoblotting;
Cys., cysticercosis; Hc., hepatic cancer; Schis., schistosomiasis.
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serodiagnosis of AE [62]. Both native components
showed very high specificity and sensitivity in
western blots, and their cloning, expression as
recombinant molecules and immunological eval-
uation are tasks that should be undertaken in the
future. Serodiagnosis of human AE using ELISA
and western blot assays, based on purified or
recombinant antigens, have been used widely
throughout the world in recent years (reviewed
by Ito et al. [63]).
Protoscolex and adult excretory–secretory
products
In contrast to E. multilocularis metacestode and
protoscolex somatic antigens, very little research
has been directed towards the excretory–secretory
products (ESPs) of the parasite and their potential
use for serodiagnostic purposes. Thus, the EM4
antigen gene codes for a protein that has epitopes
shared by 62-, 49- and 44-kDa native parasite
antigens [54]. These components are probably the
products of post-translational modifications of a
66-kDa precursor protein [64]. These three poly-
peptides have been detected in protoscolex and
cyst fluid, suggesting that the EM4 native antigen
is an ESP. When tested in an ELISA, the EM4
recombinant protein was E. multilocularis-specific,
albeit with poor sensitivity (37%) [64]. Later
comparative analyses demonstrated that EM4 is
a fragment of EM10. On the other hand, the
Em492 antigen appears to be synthesised within
the parasite germinal layer and is secreted either
in the vesicle fluid or towards its exterior [32]. In
the latter case, Em492 is stored transiently in the
laminated layer and released subsequently during
in-vitro metacestode culture into the surrounding
medium. Despite the fact that this molecule is
present at the host–parasite interface, its potential
for immunodiagnostic purposes has not yet been
evaluated.
In E. granulosus protoscolex ESP, two new
E. granulosus antigens of 89 kDa and 74 kDa have
been proposed as potential diagnostic molecules
for the immunodiagnosis of human CE [65]. Subse-
quent cross-reactivity studies by immunoblot and
ELISA inhibition demonstrated that E. granulosus
protoscolex ESPs share a high proportion of anti-
genic components with protoscolex somatic ex-
tracts and, to a lesser extent,with hydatidfluid [66].
Protoscolex and adult ESPs have also been
assayed as antigenic sources in the serodiagnosis
of intestinal dog echinococcosis [67,68], with 89-
and 50-kDa components showing promising fea-
tures as diagnostic antigens [68]. In addition, a
rabbit polyclonal immunoserum raised against
this antigenic extract has been used successfully
in capture ELISAs for the detection of E. granulosus
antigens released in faeces (copro-antigens) from
dogs infected naturally [69]. To our knowledge,
E. multilocularis ESPs have never been used for
serodiagnosis of the infection in definitive hosts.
Studies by Elayoubi et al. [70] and Elayoubi and
Craig [71] demonstrated that copro-antigens from
dogs infected naturally or experimentally with
E. granulosus comprised carbohydrates with
a-D-mannose and ⁄ or a-D-glucose, b-galactose
and N-acetyl-b-glucosamine residues. These car-
bohydrate moieties were associated with a signi-
ficant proportion of the copro-antigen activity in
copro-antigen ELISAs. These findings suggest
that the same phenomenon may occur in faeces
from definitive hosts infected by E. multilocularis,
and highlight the necessity for further character-
isation of these glycocomponents.
S E R O L O G I C A L D I F F E R E N T I A T I O N
B E T W E E N A L V E O L A R A N D C Y S T I C
E C H I N O C O C C O S I S
Differential diagnosis of AE and CE is important
not only with regard to treatment and prognosis,
but also for epidemiological studies. This issue is
especially critical in those regions where both
diseases occur, e.g., north America, central Eur-
ope, central Asia and China. However, because
E. multilocularis and E. granulosus antigenic ex-
tracts exhibit a high degree of cross-reactivity [48],
serological differentiation is often difficult. For
this reason, considerable research has been con-
ducted with the aim of identifying and purifying
native or recombinant species-specific echinococ-
cal antigens. The most reliable E. multilocularis
molecules available currently for differential sero-
diagnostic purposes are the Em2 and Em18
antigens. Em2 was the first echinococcal compo-
nent that allowed effective discrimination
between AE and CE patients [72]. A differenti-
ation rate of 95% was reported when Em2 was
used simultaneously in an ELISA with the antigen
Em1, which is a fraction rich in components
common to E. multilocularis and E. granulosus. The
sensitivity of the assay was improved using the
Em2plus antigen [47], which was also used
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successfully for differential serodiagnosis of AE
and CE [17].
The E. multilocularis protoscolex-derived Em18
antigen has also been used extensively for sero-
logical differentiation of AE and CE, either alone
[16,73] or in combination with E. granulosus-spe-
cific antigens [74,75]. Thus, ELISA and western
blot tests based on this component show sensi-
tivities and specificities in the ranges of 91–100%
and 77–97%, respectively. However, correct iden-
tification of native Em18 in western blots can be
hampered by other antigen components of similar
molecular size. In order to avoid false-positive
reactions, SDS-PAGE must be performed under
optimal conditions, and only sharp 18-kDa bands
should be reported as Em18 antigen [75]. This
problem has been overcome partially by the
cloning and expression of this component as a
recombinant protein (rEm18). The use of rEm18
has allowed an improvement in the differential
diagnostic performance obtained with the native
protein [16,73]. In addition, an Em18 western blot
has shown superior diagnostic sensitivity and
specificity compared with Em2plus ELISA, and
therefore appears to be more reliable for differ-
entiation of AE [17].
Currently, at least one western blot kit (Echino-
coccus Western Blot IgG; LDBIO Diagnostics,
Lyon, France) is available commercially for rout-
ine serological diagnosis and differentiation of
Echinococcus spp. This test, based on the detection
of specific IgG directed against E. multilocularis
whole larval antigen (including Em16 and Em18
antigens), allows correct differentiation between
AE and CE patients in 76% of cases, thereby
achieving similar diagnostic sensitivities to those
reported previously for the Em2plus ELISA assay
[76].
Table 3 summarises the diagnostic perform-
ance of the various tests for serological differen-
tiation of AE and CE.
F O L L O W - U P O F E . MULTILOCULARIS
I N F E C T I O N
The preferred approach for the treatment of
human AE currently involves surgery, with che-
motherapy with albendazole or mebendazole as
an alternative, especially for patients with non-
resectable lesions [77]. Although albendazole and
mebendazole are the only drugs licensed for the
treatment of human AE [78], a number of novel
chemotherapeutic agents are currently under
study. These include itraconazole, methiazole
and nitazoxanide [79], as well as synthetic geni-
stein derivatives [80]. However, because surgical
treatment is often only partially successful, and
benzimidazole-type drugs are parasitostatic
rather than parasitocidal, evaluation subsequent
to treatment is essential for the prognosis of AE
patients. Although ultrasonography, magnetic
resonance imaging, computerised tomography
and positron emission tomography are used
routinely for diagnosis and regular follow-up
imaging of cases of AE, atypical images are
difficult to interpret and can cause confusion
[81]. In this situation, detection of specific serum
antibody levels and cytokine patterns has been
shown to be a useful tool for monitoring AE
patients after treatment.
Table 3. Main characteristics of tests for serological differentiation between alveolar and cystic echinococcosis
Antigens
No. of subjects tested
Test
Echinococcus multilo-
cularis
Echinococcus granulo-
sus
ReferenceAE CE OD HS S (%) Sp (%) S (%) Sp (%)
Em1a + Em2b 31 26 – – IgG ELISA 97 – 92 – [72]
Em18b + Ag Ba 66 173 86 29 IgG IB 96 97 92 21 [75]
16b, 18b, 27b kDa 61 50 155 – IgG IB 97 95 98 98 [76]
18 kDaa,b 44 70 29 30 IgG ELISA 91 94 – – [74]
18 kDaa,b 44 70 29 30 IgG IB 91 77 – – [74]
Em18b 20 35 5 – IgG ELISA 95 95 – – [73]
Em18b 20 35 5 – IgG IB 95 92.5 – – [73]
Em18b 5 6 34 – IgG ELISA 100 95 – – [16]
EmII ⁄ 3b 5 6 34 – IgG ELISA 100 95 – – [16]
rEM10b + rEG55a 74 63 31 39 IgG ELISA 93 97 89 99 [44]
rEm18b 20 35 5 – IgG ELISA 95 90 – – [73]
rEm18b 20 35 5 – IgG IB 95 95 – – [73]
rEm18b 19 32 157 – IgG ELISA 100 99 – – [16]
AE, alveolar echinococcosis; CE, cystic echinococcosis; OD, other diseases; HS, healthy subjects; S, sensitivity; Sp, specificity; r, recombinant antigen; IB, immunoblotting.
aAntigen with high Echinococcus granulosus specificity.
bAntigen with high Echinococcus multilocularis specificity.
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Detection of specific antibody isotype levels
ELISA using the purified native Em2 antigen has
shown that 67% of AE patients who undergo
complete liver resection become seronegative
within 1 year [82], providing evidence that speci-
fic IgG antibody levels may correlate with the
clinical status of the patient. The recombinant
II ⁄ 3-10 antigen, alone or in combination with Em2
(Em2plus ELISA), has also shown its reliability in
assessing the efficacy of chemotherapy [15,83].
The fact that II ⁄ 3-10 appears to have a predictive
value in measuring metacestode viability suggests
that this antigen may be especially suited for the
follow-up of cases of E. multilocularis infection
[84]. However, other studies have shown that the
Em2 ELISA may be positive for years after
spontaneous dying out of the metacestode in
patients with calcified lesions (where the parasite
material remaining consists only of debris of the
laminated layer, the main source of the Em2
antigen). Surgical removal of the dried-out lesion
resulted in an immediate seroconversion to neg-
ative with respect to anti-Em2 antibodies [85,86].
Moreover, Wen and Craig [87] reported signifi-
cantly high levels of IgG1 and IgG4 antibodies in
84% of AE patients, suggesting that these are the
most immunodominant IgG subclasses against
the parasite infection in humans. This hypothesis
was confirmed in later studies, which found that
cured patients become seronegative for the IgG4
subclass 1 year after treatment, while aggravated
cases maintain, or even increase, specific IgG4
antibody levels [58,88,89]. Additionally, the reap-
pearance of specific IgG4 antibodies was a strong
indication of disease recrudescence. These studies
also showed that, in AE patients with progressive
disease, IgG4 antibodies recognise antigenic com-
ponents of 26, 18, 16 and 12 kDa in western blots
using parasite protoescolex antigens, while these
molecules were identified weakly or not at all in
cured or improved cases. It has been reported
previously that the 18-kDa component (Em18) can
be used successfully to differentiate active from
inactive cases of AE [90,91]. Subsequent investi-
gations using native Em18 western blots [15] and
recombinant Em18 ELISA [14] have confirmed
that IgG responses against this antigen decline to
negative in cured cases and in a high proportion
of stabilised patients.
Detection of specific IgG antibodies directed
against E. multilocularis AP has also been pro-
posed as a method for monitoring the course of
the infection in AE patients [92]. This membrane-
bound enzyme has very high activity in the
parasite metacestode, suggesting that AP plays
an important role in the exchange of nutriments
[93]. Anti-AP antibody levels were demonstrated
by ELISA to be very sensitive to any intervention
(surgery, drainage) into the parasitic lesions,
showing a good correlation with clinical data.
Elevated levels of IgE antibodies are a charac-
teristic feature of many helminthic infections.
Although IgE may provide protection against a
limited spectrum of parasite species, particularly
nematodes [94], it also stimulates mast cells and
basophils to release an array of mediators
involved in such physiological events as allergy,
asthma and anaphylaxis [95]. Thus, in E. granulo-
sus infection, the presence of IgE is associated
with pathological allergic reactions [96]. In addi-
tion, IgE levels decrease rapidly in the serum of
CE and AE patients following surgery or success-
ful chemotherapy, suggesting that the IgE level
could be a useful marker for the outcome of the
diseases [97,98]. In the same way, Ortona et al.
[99] recommended the detection of IgE specific to
the recombinant antigen EgEF-1b ⁄ d (a protein
homologous to the subunit of elongation factor-1)
for serodiagnosis of asymptomatic false-negative
CE patients. Several studies have also shown that
increased levels of specific IgE in AE patients
correlate with a progressive state of disease
[88,100,101]. Recently, a new diagnostic test for
quantitative determination of specific IgE and IgG
against crude metacestode antigen of E. multilo-
cularis has been developed, based on the com-
mercial immunoassay ImmunoCAP (Phadia AB,
Uppsala, Sweden). The test showed a sensitivity
of 73.6% for specific IgE determination, providing
a useful tool for evaluating specific IgE levels
during the clinical course of AE [102].
Detection of specific cytokine levels
New strategies have been developed in recent
years in an attempt to improve the prognosis and
follow-up of AE patients after surgical or phar-
macological treatment. A strong cellular and
antibody response is elicited by E. multilocularis
infection in humans [103,104], causing large gra-
nulomatous lesions, necrosis, host tissue destruc-
tion, and, ultimately, organ failure [27]. Previous
in-vitro and in-vivo investigations have shown
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that a predominantly humoral (Th2 lymphocyte-
mediated) immune response is associated with
progression of the disease, whereas a mainly
cellular (Th1 lymphocyte-mediated) immune re-
sponse leads to resistance against the parasite in
both AE patients and infected mice [105–107]. The
balance between the Th1 and Th2 lymphocyte
populations is regulated tightly by cytokines
through an intricate interplay of positive and
negative regulatory signals. Thus, Th1 lympho-
cytes secrete IL-2 and interferon-c, whereas Th2
lymphocytes produce IL-4, IL-5, IL-6 and IL-10,
and cooperate with B-cells to generate IgM, IgG,
IgA and IgE responses [108]. In mice infected
experimentally with E. multilocularis, a Th1 cyto-
kine profile, including IL-2 and interferon-c, has
been found to be associated with slow parasite
growth, whereas mixed secretion of Th1 and Th2
(especially IL-5 and IL-10) was associated with
rapid parasite growth [96,109]. This indicates that
a gradual shift towards a Th2 response may be a
feature of disease progression, with this polarisa-
tion (and also the switch to IgE synthesis in
B-cells) being dependent on IL-4 [110].
Stimulation of peripheral blood mononuclear
cells (PBMCs) in AE patients with crude parasitic
antigens induces specifically the expression of
IL-5 at the gene and protein levels. Interestingly,
no evidence of IL-5 mRNA synthesis could be
demonstrated in PBMCs from patients after sur-
gical removal of the lesions, a fact that suggests an
association between IL-5 mRNA expression and
the clinical status of the disease [111]. However,
this hypothesis was not confirmed by Godot et al.
[112], who found no significant difference in IL-5
mRNA expression between patients with active
disease and individuals with abortive lesions.
Nevertheless, spontaneous secretion of IL-10 by
PBMCs is the immunological hallmark of patients
with progressive forms of AE. Thus, AE patients
with active disease secrete significantly higher
levels of IL-10 than those with cured or abortive
lesions, whereas an intermediate level of this
cytokine was found in the group of patients with
positive E. multilocularis serology but no clinical
symptoms [112].
A similar, although less clear, IL-10 pattern was
found in sera from AE patients in in-vivo experi-
ments [106]. Further investigations demonstrated
that lymphocytes from the centre of the peripar-
asitic granuloma produce 4–5.5-fold more IL-10
than PBMCs, providing evidence that IL-10 has a
key role in the host–parasite interaction in AE
[113]. Nevertheless, other in-vitro studies, based
on stimulation of PBMCs by viable E. multilocu-
laris vesicles, failed to demonstrate significant
differences in IL-10 expression among the differ-
ent states of the infection [114], or even between
patients and controls [115]. Other cytokines that
have been found at elevated levels in AE patients
are IL-8, IL-12 and IL-13 [106,114,115]. In partic-
ular, IL-12 has shown a good correlation with the
course of the infection. Taken together, these
results demonstrate that the detection of specific
cytokine levels, especially for IL-10 and IL-5, and
to a lesser extent for IL-12, may be a useful tool for
predicting the actual state of clinical disease in AE
patients after surgical and ⁄ or pharmacological
treatment.
I M M U N O D I A G N O S I S O F
E . MULTILOCULARIS I N T H E
D E F I N I T I V E H O S T
Although wild foxes of the genera Vulpes and
Alopex are the typical definitive hosts for the adult
stage of E. multilocularis, other wild canids (inclu-
ding coyotes, wolves and raccoon dogs) and wild
cats can also serve as definitive hosts in some
endemic areas. In addition, a synantrophic cycle
is known to exist under certain epidemiological
situations, with domestic dogs and cats as defin-
itive hosts [23]. Immunological methods, based on
the detection of specific circulating antibodies
against crude parasite antigens or affinity-puri-
fied Em2 antigen, have been evaluated for the
diagnosis of E. multilocularis in final hosts. How-
ever, because specific antibody levels can persist
for long periods, even when the infection has
resolved, this methodology is unable to determine
the actual intestinal infection status in individual
animals [18,19,116]. Currently, copro-antigen
ELISA (CpAg ELISA) is the immunodiagnostic
test of choice for the detection of Echinococcus
infection in the definitive host [21,48]. This tech-
nique combines several important features that
make it a powerful tool for large-scale investi-
gations. Thus, E. multilocularis copro-antigens are
detectable during the prepatent period as early as
3–6 days post-infection in foxes and dogs infected
experimentally [22,117,118], and CpAg ELISA
results show a good correlation with the intestinal
worm burden [118–121]. In addition, CpAg ELISA
values decrease to negative levels 2–3 days after
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elimination of the parasite from the definitive
host, thereby allowing an accurate assessment of
the current status of the infection [121,122].
The first CpAg ELISA for the detection of
E. multilocularis metabolic products in faecal sam-
ples from foxes and other carnivores was devel-
oped by Deplazes et al. [118]. With the use of
protein-A-purified antibodies raised against
E. granulosus ESPs, a strong correlation was
reported between CpAg ELISA optical density
values and diagnostic sensitivity in natural infec-
tions. Thus, the sensitivity was 18% for foxes with
<100 worms, 39% for those with 100–1000 worms,
and 100% for those with >1000 worms. No cross-
reactions were observed with samples from foxes
infected with non-Echinococcus cestodes or nema-
todes. The sensitivity of this test was subse-
quently improved, using antibodies directed
against somatic worm antigens, to 40% in animals
infected with <20 worms, and to 93.3% in foxes
with >21 worms [121]. This CpAg ELISA has been
used successfully for detection of E. multilocularis
copro-antigen in field faeces, with the ability to
detect medium and high prevalences of E. mul-
tilocularis in fox populations [123], and for inves-
tigating the effect of anti-helminthic baiting in
urban areas with high parasite endemicity [124].
In an attempt to improve the test sensitivity,
Kohno et al. [22] developed a new CpAg ELISA
test based on the monoclonal antibody EmA9.
This antibody was directed against a glycosylated
antigen of E. multilocularis adult worms, although
it also recognised ESPs of the parasite. This copro-
antigen is thermo-resistant, so faecal samples can
be used safely after incubation at 70C to inacti-
vate egg infectivity without compromising the
test efficiency. The diagnostic performance of the
assay with naturally infected foxes showed a
sensitivity of 87% [125], which was improved to
95% by using an avidin ⁄ biotin system for ampli-
fication of the monoclonal antibody EmA9 signal
[126]. No false-positive reactions with other
helminth infections, including those with Taenia
taeniaeformis, Taenia crassiceps, Trichuris vulpis and
Toxocara canis, were observed [22,120,122],
although cross-reactivity with copro-antigens in
dogs infected with E. granulosus or Taenia hydati-
gena has been reported previously [127,128].
However, further work is required to evaluate
more accurately the diagnostic specificity of the
EmA9 antibody, since only a comparatively low
number of faecal samples were tested in these
studies. In addition, the CpAg ELISA detection
limit was estimated as 4 ng antigen ⁄ g faeces [122].
Using this test, parasite copro-antigens were
detected as early as 3 days post-infection in dogs
infected experimentally [22] and 6 days post-
infection in foxes infected experimentally [117].
This CpAg ELISA has been used widely in field
surveys in areas of high endemicity in Hokkaido,
Japan, in order to estimate the prevalence of
E. multilocularis in naturally infected fox popula-
tions [125,126,129,130] or to assess the effective-
ness of anti-helminthic baiting campaigns [131].
Copro-antigens were detected consistently in
these studies, regardless of faecal condition, and
even in faeces passed >1 week previously [132], a
fact that demonstrates the high stability of the
antigen recognised by the EmA9 antibody.
A novel double-sandwich ELISA, based on
polyclonal antibodies raised against somatic
E. multilocularis antigens, has been developed
recently by Machnicka et al. [20]. Better differen-
tiation between positive and negative faecal sam-
ples was achieved by the previous selection of
specific parasite antibodies directed against soma-
tic antigens of the adult worm, allowing improve-
ment of the diagnostic specificity. This CpAg
ELISA is particularly well-suited for the mass
screening of definitive host populations with a
low prevalence of E. multilocularis.
Currently, at least one CpAg ELISA kit for the
detection of both E. multilocularis and E. granulo-
sus in the definitive host is available commercially
(Chekit Echinotest; Dr Bommeli AG, Bern,
Switerland). Table 4 summarises the efficacy of
the available copro-antigen ELISA tests for the
immunodiagnosis of E. multilocularis infection in
definitive hosts.
I M M U N O D I A G N O S I S O F
E . MULTILOCULARIS I N
I N T E R M E D I A T E A N D A B E R R A N T
H O S T S
Although identification of the larval stage of
E. multilocularis in intermediate or aberrant hosts
is not an important priority, diagnosis of the
infection is mainly based on macroscopic and
histological examinations, with confirmation of
doubtful cases by immunological tests or PCR [7].
Thus, specific antibody responses against the
Em18 antigen have been reported in naturally
infected voles, the most common intermediate
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host for E. multilocularis [133]. However, serolog-
ical tests are not feasible for determination of the
parasite’s prevalence in wild populations [134].
A number of mammalian species have been
described as aberrant hosts of the metacestode
of E. multilocularis, including domestic and wild
pigs, horses, monkeys, and even domestic dogs
(reviewed by Deplazes and Eckert [23]). Specific
circulating antibodies against the parasite anti-
gens Em2, Em2(G11) and II ⁄ 3-10 have been
detected in many of these hosts. Thus, detection
of antibodies against the Em2 antigen has been
shown to be a useful approach for detecting the
parasite in cynomolgus monkeys [135,136] and
lowland gorillas [137]. In addition, Em2(G11) and
the somatic Em10CH antigen have been used
successfully to monitor the early development of
E. multilocularis lesions in pigs infected experi-
mentally with parasite eggs [138]. However, the
diagnostic performance of these tests is still under
evaluation.
M O L E C U L A R D I A G N O S I S O F
E . MULTILOCULARIS I N F E C T I O N
In an attempt to improve the detection of E. mul-
tilocularis infection, powerful molecular tech-
niques (including PCR, Southern blot and
northern blot analyses) have been developed
[24,139,140]. For diagnostic purposes, PCR shows
the best features, providing rapid amplification of
parasite-specific DNA (or RNA) sequences, and
thereby greatly increasing the sensitivity of the
assay. However, the use of PCR for routine
diagnostic or large-scale epidemiological studies
is limited by its high cost and complexity. In
addition, this methodology requires highly
purified nucleic acids to avoid the inhibitory
effect of uncharacterised substances. Thus, PCR is
generally used for confirmation of positive or
suspected positive results obtained with other
diagnostic tests. In humans, PCR is used mainly
for the direct detection of parasite nucleic acid in
biological specimens that are usually obtained by
fine needle aspiration biopsies [141–143]. This
approach, which has been shown to be E. multi-
locularis-specific, has also been used successfully
for diagnostic purposes in other intermediate
hosts, including voles [144] and wild boars
[145]. In addition, PCR has shown good potential
for determining the viability and growth activity
of the E. multilocularis metacestode [143,146]. In
the intermediate host, PCR allows the detection of
parasite DNA in faecal material with high
specificity (nearly 100%) and sensitivity (at least
89%) [147]. Copro-diagnosis by PCR has been
used for the diagnosis of E. multilocularis infection
in foxes [119,148], dogs [149,150] and wolves
[151].
C O N C L U S I O N S A ND P E R S P E C T I V E S
Considerable progress has been made recently in
the identification and characterisation of new
molecules, including native, partially purified
and recombinant antigens, for the immunodiag-
nosis of E. multilocularis infection. In particular,
recombinant proteins are typically associated
with a better diagnostic performance than the
homologous native proteins, with the added
advantage that their production in large quantity
allows standardisation of the antigen source. As a
result, serological techniques have improved
significantly in terms of their diagnostic features.
Table 4. Main characteristics of copro-antigen ELISA tests for immunodiagnosis of Echinococcus multilocularis infection in
definitive hosts
Antiserum, mAb or
commercial kit Definitive host
No. of animals tested
S (%) Sp (%) Cross-reactions ReferenceWith E.m. Without E.m.
Anti-E.g. ESP Ad. Foxa 59 40 18–100c 98 None [118]
Anti-E.m. S. Ad. Doga,b 9 175 100 97 E.g., Taenia spp. [121]
Anti-E.m. S. Ad. Foxa 55 31 40–93c 93 – [121]
mAb Em9 Foxa 39 32 95 100 None [120]
mAb Em9 Foxa 123 307 87 – – [125]
Anti-E.m. S. Ad. Foxa 62 146 98 92 Taenia spp., M.l., Tox., Unc. [20]
Chekit Echinotest Foxa 120 112 31–100c 95 – [119]
E.m., Echinococcus multilocularis; S, sensitivity; Sp, specificity; ESP, excretory–secretory products; S., somatic extract; Ad., adults; mAb, monoclonal antibody; E.g., Echinococcus
granulosus; M.l., Mesocestoides lineatus; Tox., Toxocara; Unc., Uncinaria.
aNatural infection.
bExperimental infection.
cDepending on the parasite burden.
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A wide spectrum of reliable serological methods
is now available for differentiation of AE from
other diseases, including CE, for routine screen-
ing and epidemiological surveys, and for monit-
oring AE patients after surgical and ⁄ or
chemotherapeutic treatment. The improvement
achieved has resulted in the proposal that sero-
logical tests should become the first choice for
diagnosis of AE, with imaging techniques as
confirmatory tests [63]. However, despite the
unquestionable progress that has been made,
much work remains to be done to improve the
serodiagnosis of AE. For example, the discrete
epitopes of the identified antigens that could be
mimicked by synthetic peptides should be
defined, thereby allowing the measurement of
antibodies directed against very specific antigenic
determinants. The evaluation of novel native
antigens, recombinant proteins and synthetic
peptides (individually or in combination) is a
further task that should be undertaken in the near
future. In addition, research is required to eluci-
date and ⁄ or clarify the biological role of the
various antigens, as well as the molecular basis on
which these molecules are expressed and regula-
ted. New developments in genomics, proteomics
and microarray analysis should provide insights
into these important issues [5].
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